SBIA
ACHN

Sheaff Brock Investment Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,300
Closed -$55K – 586
2017
Q3 		$55K Buy
12,300
+2,300
+23% +$10.2K 0.01% 551
2017
Q2 		$46K Sell
10,000
-1,000
-9% -$4.02K 0.01% 590
2017
Q1 		$46K Hold
11,000
– – 0.01% 583
2016
Q4 		$45K Buy
+11,000
New +$58.5K 0.01% 593

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sheaff Brock Investment Advisors's ACHN Position: Q4 2017 in Review

Sheaff Brock Investment Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q4 2017, closing a stake of 12,300 shares — an estimated $55K sold.

Sheaff Brock Investment Advisors first reported a position in ACHN in Q4 2016 and held it in 4 quarters. The position peaked at $55K in Q3 2017. 149 funds tracked by Wall St. Rank hold ACHN as of Q4 2017.

  • Sheaff Brock Investment Advisors reported no remaining Achillion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 12,300 Achillion Pharmaceuticals shares in Q4 2017, an estimated $55K.
  • Sheaff Brock Investment Advisors first reported a position in Achillion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Sheaff Brock Investment Advisors's Achillion Pharmaceuticals position peaked at $55K in Q3 2017.
  • 149 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2017.

Based on Sheaff Brock Investment Advisors's 13F filing for Q4 2017, filed 12 Feb 2018.